Editorial
On the cusp of a sea change in biliary tract cancer
Chinese Clinical Oncology
2020;
9
(1)
:1
.
(28 February 2020)
Review Article
Immune checkpoint inhibitor therapy in biliary tract cancer (cholangiocarcinoma)
Chinese Clinical Oncology
2020;
9
(1)
:2
.
(28 February 2020)
Modern gastrointestinal endoscopic techniques for biliary tract cancers
Chinese Clinical Oncology
2020;
9
(1)
:3
.
(28 February 2020)
Cholangiocarcinoma: a site-specific update on the current state of surgical management and multi-modality therapy
Chinese Clinical Oncology
2020;
9
(1)
:4
.
(28 February 2020)
Biliary tract cancers: systemic therapy for advanced disease
Chinese Clinical Oncology
2020;
9
(1)
:5
.
(28 February 2020)
Biliary tract cancer and genomic alterations in homologous recombinant deficiency: exploiting synthetic lethality with PARP inhibitors
Chinese Clinical Oncology
2020;
9
(1)
:6
.
(28 February 2020)
Targets for therapy in biliary tract cancers: the new horizon of personalized medicine
Chinese Clinical Oncology
2020;
9
(1)
:7
.
(28 February 2020)
Interventional radiology approaches for intra-hepatic cholangiocarcinoma
Chinese Clinical Oncology
2020;
9
(1)
:8
.
(28 February 2020)
Guideline
Guidelines for biliary stents and drains
Chinese Clinical Oncology
2020;
9
(1)
:9
.
(28 February 2020)
Review Article
Radiation dose escalation for locally advanced unresectable intrahepatic and extrahepatic cholangiocarcinoma
Chinese Clinical Oncology
2020;
9
(1)
:10
.
(28 February 2020)
Disclosure:
The focused issue “Biliary Tract Cancers” was commissioned by the Editorial office, Chinese Clinical Oncology without any sponsorship or funding. Milind Javle served as the unpaid Guest Editor for the focused issue.